

BENEFITS OF VENTRIPOINT'S VMS™ SYSTEM TO BE PRESENTED AT PRESTIGIOUS HEART CONFERENCE

***** Dr. Shelby Kutty will present a novel use of the VMS™ at EUROECHO *****

Seattle, Washington, December 7, 2011– VentriPoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF.PK) today announced that a clinical medical research paper on the novel application of VentriPoint's VMS™ heart analysis system to patients with congenital heart disease will be presented at the Annual Congress of the European Association of Echocardiography, EUROECHO, in Budapest, Hungary, December 7 -10th, 2011.

In a presentation by Dr. Shelby Kutty, Assistant Professor of Pediatrics at the University of Nebraska College of Medicine, he concluded, "These results demonstrate clinical feasibility of quantifying systemic right ventricle volumes and function in adolescents and young adults with repaired CHD..." The presentation entitled "*Echocardiography Knowledge-Based Reconstruction for Derivation of Volumes and Ejection Fractions for the Systemic Right Ventricle in Patients with Congenital Heart Disease (CHD)*" will be presented on December 10, 2011.

"We know that we are just at the beginning of realizing the potential of VMS™," stated Dr. George Adams, President & CEO of VentriPoint. "It is fulfilling to see our users extend the clinical application of VMS™ beyond 'Blue Babies' to another type of congenital heart disease, systemic right ventricle."

The Company will be exhibiting at EUROECHO. In support of this event, VentriPoint announces the appointment of Victor Ton, European Sales Manager. Victor has more than 22 years of sales and marketing experience in the medical device industry, especially in the cardiology field.

"We are so pleased that Victor Ton has joined our team," acknowledged Mr. Amol Karnick, VP Sales and Business Development. "He is an extremely valuable addition at this point in the Company's development. We are presently focused on sales in Europe and Victor's extensive experience and background will certainly benefit us in our execution of our sales strategy in that market."

About Victor Ton

Mr. Ton has worked in the areas of patient monitoring (Mennen Medical), stress test, holter monitor recording, catheter lab recording systems (Quinton Instrument Corporation and Schwarzer GmbH) and the field of electrophysiology (Quinton Electrophysiology Corporation, EPMedSystems Inc. and Cardiotek B.V.) Previously he worked as a catheter lab technician at the OLVG Hospital in Amsterdam for 10 years. With EPMedSystems, he was responsible for sales and marketing for the EMEA countries (Europe, Middle East, Africa), as well as both direct European offices in France and the Netherlands as Director of International Sales. Working for both Cardiotek and Schwarzer GmbH, he was International Sales Director EMEA with a spectrum of responsibilities including sales and marketing activities, clinical training, as well as revenue growth and product development. He holds a B.S. in Engineering and will be working from the Netherlands.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

VentriPoint Diagnostics Ltd.

Dr. George Adams, CEO

Telephone: (206) 283-0221, ext. 401

email: gadams@ventripoint.com

Howard Group Inc.

Peter Weichler/David Burwell

Telephone: 1.888-221-0915 or 403-221-0915

email: Peter@howardgroupinc.com
Dave@howardgroupinc.com

Cautionary Note Regarding Forward-Looking Statements: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

